FindTrial
Sign In

IV THROMBOLYSIS(rt PA-Alteplase) AS TREATMEANT IN SEVERE COVID ARDS

IV THROMBOLYSIS(rt PA-Alteplase) AS TREATMEANT IN SEVERE COVID ARDS:A case series. - rt-PAC19SRDS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/08/035445
Enrollment
12
Registered
2021-08-05
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J80- Acute respiratory distress syndrome Health Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

None listed

Sponsors

COLUMBIA ASIA REFERRAL HOSITAL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Severe COVID -19 ARDS (pao2:fio2 ratio <100) who are admitted to ICU

Exclusion criteria

Exclusion criteria: Prior intracrainial hemorrhage Iaschemic stroke within 3 months Uncontrolled hypertension(BP >180/110) Major surgery within 3 months prior Non compressible vascular puncture

Design outcomes

Primary

MeasureTime frame
ICU MORTALITYTimepoint: 28 DAY ICU mortality—

Secondary

MeasureTime frame
ICU length of stay. Change in pao2/fio2 P/F ratio. Timepoint: BEFORE rt PA POST rt PA 24HRS, 48HRS, 1 WEEK, @ discharge—

Countries

India

Contacts

Public ContactDr PRATHIBHA G A

COLUMBIA ASIA HOSPITAL YESHWANTHPUR

prathibhaga@gmail.com9448996024

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026